Singapore Immunology Network & Fluidigm Greater Asia High-Dimensional (HiDi) Immune Profiling Research Award 2021

 

Congratulations to our Research Award winners

Our Grand Award goes to SMART CAMP on its project that seeks to deeply profile anti-TIM-3 CAR T-cells and identify the impact of manufacturing in microbioreactors against G-Rex® well-plates.


Grand Awardee

Institute

Project Title

SMART-CAMP,
Singapore
Phenotypical profiling of anti-TIM-3 CAR T-cells versus anti-CD19 CAR T-cells manufactured in microbioreactors versus G-Rex® well-plates

Regular Awardees

Institute

Project Title

University of South Australia,
Australia
The single-cell mass cytometry approach revolutionizes the understanding of the heterogeneity of human immune cell populations and their interactions with gold nanoparticles in human blood samples
Asan Institute for Life Sciences,
Korea
Phenotyping of liver transplant acceptance and rejection immunity
Singapore Immunology Network,
Singapore
HiDiACE: Demystifying the immunopathology underlying Asian Childhood Eczema (ACE) using High Dimensional immune profiling
Monash University Malaysia,
Malaysia
Characterization of the Immune Response in Orang Asli Population Infected with Intestinal Parasites.
Singapore Immunology Network,
Singapore
Understanding the immunopathogenesis of secondary Hemophagocytic Lymphohistiocytosis (HLH) through deep profiling of immune subsets.

This program selects six abstracts in the field of immunology, where researchers are on course to profile all major immune cell types present within human blood tissue. The awarded research will be performed using a combination of Fluidigm’s Maxpar® Direct™ Immune Profiling Assay™ and Helios™, a CyTOF® mass cytometer. Designed as a simple, single-tube workflow, the system brings together CyTOF technology on the CyTOF XT™ and Helios™ mass cytometry systems, a dry-format 30-marker antibody panel and automated Maxpar Pathsetter™ software so you can easily identify 37 immune cell populations. The Maxpar Direct Immune Profiling System has been adopted for use by multiple consortia and in clinical research studies based on its ease of use and reproducibility lot-to-lot, run-to-run and site-to-site1.

All awarded projects will be run by the SIgN Mass Cytometry Platform, Fluidigm’s first Center of Excellence for mass cytometry and Imaging Mass Cytometry™ in Singapore and Southeast Asia2.

Visit our website for more information on this research award

Interested in future Research Awards to jump-start your journey with CyTOF technology? Contact us at gra-marketing@fluidigm.com with your research interest.


Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only, not for use in diagnostic procedures. For more information see www.fluidigm.com/legal/notices.